RxDoctor Payments DataLook up a doctor →

David Wohl, MD

Infectious Disease · Chapel Hill, NCNPI 1841239308

Payments from drug & device makers

$1,332,127in general payments, 2019–2025

Across 527 payments — averaging $2527.76 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$604K
  • Merck$399K
  • Viiv Healthcare Company$242K
  • EMD Serono, Inc.$29K
  • GSK$17K
  • Theratechnologies Inc.$13K
  • plus $29K from 5 others
$164,450in research payments, 2019–2025

Across 2 payments — averaging $82,225 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$164K

What the payments were for

  • Consulting fees$534,93174%
  • Speaking & faculty fees$15,6422%
  • Grants$8030%
  • Travel & lodging$166,01823%
  • Food & beverage$7,8341%
  • Education$4990%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead244$603,794
Merck86$398,594
Viiv Healthcare Company123$242,383
EMD Serono, Inc.13$28,691
GSK1$17,280
Theratechnologies Inc.9$12,641
Janssen Scientific Affairs, LLC20$9,989
Janssen Products, LP18$8,545
Regeneron8$6,028
Shionogi Inc1$3,182
Johnson & Johnson4$1,000

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,332,127 in reported general payments places this provider in the 95th percentile of 250 infectious disease providers in North Carolina.

See all infectious disease providers in North Carolina

Medicare billing

Part B allowed, 2024
$16,894
Medicare patients
53
Services billed
187

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BiktarvyBictegrav/Emtricit/Tenofov Ala253$1,040,462
TivicayDolutegravir Sodium183$511,794
DescovyEmtricitabine/Tenofov Alafenam171$380,692
DovatoDolutegravir Sodium/Lamivudine42$121,334
OdefseyEmtricitab/Rilpiviri/Tenof Ala27$118,589
CabenuvaCabotegravir/Rilpivirine19$107,758
IsentressRaltegravir Potassium38$78,761
PrezcobixDarunavir/Cobicistat25$64,634
GenvoyaElviteg/Cob/Emtri/Tenof Alafen12$48,410
PifeltroDoravirine24$41,910
JulucaDolutegravir/Rilpivirine11$38,014
Etravirine25$26,353
CreonLipase/Protease/Amylase11$19,161
EliquisApixaban14$17,277
JardianceEmpagliflozin14$13,472

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GileadBiktarvy, Descovy, Genvoya$603,794$1,469,564436 claims
Viiv Healthcare CompanyTivicay, Dovato, Cabenuva, Juluca$242,383$778,900255 claims
MerckIsentress, Pifeltro$398,594$120,67162 claims
Johnson & JohnsonPrezcobix$1,000$64,63425 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 250 infectious disease providers in North Carolina.

Other infectious disease in Chapel Hill

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →